Purevax RCP FeLV
Active substance
ATC code
Species
Cats.
Indications
Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs,
- against feline panleucopenia to prevent mortality and clinical signs,
- against leukaemia to prevent persistent viraemia and clinical signs of the related disease.
Onsets of immunity:
- Rhinotracheitis, calicivirus and panleucopenia components: 1 week after primary vaccination course.
- Feline leukaemia component: 2 weeks after primary vaccination course.
Duration of immunity:
- Rhinotracheitis, calicivirosis and panleucopenia components: 1 year after primary vaccination course and 3 years after the last re-vaccination. - Feline Leukaemia component: 1 year after the last re-vaccination.
Dose to be administered and administration route
Subcutaneous route.
Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formation.
Visual appearance after reconstitution: slightly yellow suspension with presence of cell debris in suspension.
After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent (depending on the presentation chosen) inject one dose of vaccine according to the following vaccination scheme:
Primary vaccination course:
- first injection: from 8 weeks of age, - second injection: 3 to 4 weeks later.
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9 to 12 weeks of age born from queens, which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Revaccination:
- the first revaccination must be carried out for all components one year after the primary vaccination course,
- Subsequent revaccinations:
- Feline leukaemia component: every year.
- Rhinotracheitis, calicivirosis and panleucopenia components: at intervals of up to three years.
Adverse reactions
Transient apathy and anorexia as well as hyperthermia (lasting usually for 1 or 2 days) were commonly observed during safety and field studies. A local reaction (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most was commonly observed during safety and field studies.
Emesis (mostly within 24 to 48 hours) has been observed in very rare cases based on post-marketing safety experience.
A hypersensitivity reaction has been observed uncommonly in field studies, which may require appropriate symptomatic treatment.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals treated in 100 animals)
- uncommon (more than 1 but less than 10 animals treated in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 04491/5054 |
| EAN | 4028691577942 |
